Pfizer: further positive results in Lyme disease
(CercleFinance.com) - France's Valneva and Pfizer have announced further positive results, including data after a booster dose, from the Phase II VLA15-202 study evaluating the immunogenicity and safety of their Lyme disease vaccine candidate, VLA15.
Further evaluation at month 18 showed that antibody levels decreased in all vaccine groups, although remained above baseline, confirming the need for a booster regimen.
Both partners added that VLA15 was safe and well tolerated for all doses and in all age groups tested. No serious side events were observed in any of the groups that received the vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Further evaluation at month 18 showed that antibody levels decreased in all vaccine groups, although remained above baseline, confirming the need for a booster regimen.
Both partners added that VLA15 was safe and well tolerated for all doses and in all age groups tested. No serious side events were observed in any of the groups that received the vaccine.
Copyright (c) 2021 CercleFinance.com. All rights reserved.